Clinical Trials Logo

Clinical Trial Summary

This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany. Prospective subjects will be recruited from a patient population previously characterized in an observational study, and from referrals within the German CAPS community; SchS subjects will be recruited through the Charité Patient pool.

The Baseline phase will begin with the Screening visit (day -21 = Visit 1) and continue for three weeks; DHAFs (Daily Health Assessment Forms) will be collected from all subjects from Day - 21 to Day 0. DHAF information including MWAS (Muckle-Wells Activity Score), or SCHAS (Schnitzler Activity Score) values from this period will be used for the baseline phase evaluation. Inclusion to receive rilonacept will occur on day 0 (= Visit 2).

On day 0 eligible subjects will receive a loading dose of two subcutaneous (S.C.) injections of rilonacept for a total of 320 mg. Subsequent study drug injections of rilonacept 160 mg will be administered once a week for four weeks. After subjects complete this initial 4-week treatment phase, they will be eligible to receive rilonacept 160 mg once weekly for 48 weeks during the extended treatment phase.

DHAFs will be used to assess symptoms throughout the study. Overall a max. of 12 subjects with either MWS or SchS will be enrolled.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01045772
Study type Interventional
Source Charite University, Berlin, Germany
Contact
Status Completed
Phase Phase 2
Start date January 2009
Completion date September 2010

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04213274 - Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome Phase 2
Completed NCT01245127 - Ilaris (Canakinumab) in the Schnitzler Syndrome Phase 2
Terminated NCT03595371 - Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome Phase 2
Completed NCT01390350 - Ilaris® Effects in Schnitzler Syndrome (ILESCH) Phase 2
Completed NCT00933296 - Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors N/A
Completed NCT01276522 - Efficacy and Safety of Canakinumab in Schnitzler Syndrome Phase 2
Recruiting NCT05200715 - AutoInflammatory Disease Alliance Registry (AIDA)